Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

Thursday, September 4, 2008

Games to enjoy

Provided by: MS Views and Related News OT, Susan D,,
Here are some games for you to play.
Have some fun:

Kenai River Run (fishing)


Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.

============================================

BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA

Article contributed by Olga R., in Miami

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 4 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.

» Read More

Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Opexa Therapeutics and Myelin Repair Foundation Partner on Novel Multiple Sclerosis Research Program

Market Watch Business Wire

Collaboration to Identify Therapeutically Relevant Biomarkers and Offer Key Insight for Further Clinical Development of Tovaxin(R)

Last update: 7:30 a.m. EDT Sept. 3, 2008

THE WOODLANDS, Texas, Sep 03, 2008 (BUSINESS WIRE) -- Opexa Therapeutics, Inc. a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced the establishment of a novel MS research partnership with the Myelin Repair Foundation, Inc. (MRF). As part of this collaboration, Opexa and the MRF will work to identify therapeutically relevant biomarkers in MS that may provide important insight to support the continued development of Tovaxin(R), Opexa's T-cell vaccine currently in Phase IIb clinical testing in MS patients. In addition, biomarkers identified as part of the research program may also assist in guiding the discovery and development of novel diagnostics and treatments for MS.


» Read More



Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.

============================================

Monday, September 1, 2008

New Zealand has become the first country in the world to fully research the incidence of multiple sclerosis (MS) over an entire country.

Stuff.co.nz - New Zealand
Monday, 01 September 2008


A jointly funded report by the Multiple Sclerosis Society and the Health Research Council, released today, says that close to 3000 people have been clinically identified as having MS (or 71.9 per 100,000 people), with a further 1200 potentially with the condition.

The $500,000 report, which took nearly two years to compile, shows that the prevalence of MS is significantly related to regions of the country -- increasing from 50.8 people per 100,000 in Northland to 134.6 people per 100,000 in Southland.

» Read More


Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================